CorestemChemon Inc. is a pioneering biopharmaceutical company in South Korea, specializing in stem cell therapies and non-clinical contract research organization (CRO) services. Established as the first private testing institution in the country, the company provides a comprehensive suite of non-clinical testing services, including toxicity and efficacy assessments, which are essential for the development of pharmaceuticals, food products, cosmetics, chemicals, and pesticides.

CorestemChemon is dedicated to advancing stem cell-based drug development, currently focusing on neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and cerebellar ataxia, as well as autoimmune disorders like lupus and fibrosis. Their non-clinical CRO division conducts rigorous preclinical studies to ensure compliance with stringent regulatory standards across various sectors, including biopharmaceuticals and medical devices. Committed to continual innovation and research collaboration, CorestemChemon aims to make significant contributions to the global biopharmaceutical landscape.